QUAIS OS FATORES DE RISCO PARA O DESENVOLVIMENTO DE HIPERCALIEMIA?

Referências

1. Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol. 2014;10:653-662.

2. Rosano GMC, Tamargo J, Kjeldsen KP, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2018;4:180-188.

3. National Kidney Foundation. Chronic Kidney Disease (CKD) Symptoms and causes. Published 15 February 2017. Acedido em janeiro de 2023, em: https://www.kidney.org/atoz/content/about-chronic-kidney-disease.

4. Chomicki J, Klem P, Marrs J. Evaluation of the incidence of hyperkalemia in patients prescribed spironolactone for the treatment of resistant hypertension. Presented at Journal of the American Society of Hypertension 8(4S) e27e34(2014).

5. SNS24. Hipertensão arterial. 2022. Disponível em: https://www.sns24.gov.pt/tema/doencas-do-coracao/hipertensao-arterial/; acedido em janeiro de 2023.

6. Jarman PR, Kehely AM, Mather HM. Hyperkalaemia in diabetes: prevalence and associations. Postgrad Med J. 1995;71:551-552.

7. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;33(Suppl 1):S62-S67.

8. Latts LM, Reaven NL, Funk SE, et al. Hyperkalemia is prevalent in patients with cardiorenal comorbidities. Presented at the ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA. Poster PVC33.

9. Guidelines da European Society of Cardiology (ESC) para o Diagnóstico e Tratamento da Insuficiência Cardíaca Aguda e Crónica, European Heart Journal 2016;37:2129-2200

10. Hollander-Rodriguez JC, Calvert JF Jr. Hyperkalemia. Am Fam Physician 2006;73:283-290.